<DOC>
	<DOCNO>NCT01166646</DOCNO>
	<brief_summary>The purpose study determine whether investigational lotion effective treatment moderate severe plaque psoriasis comparison approve cream .</brief_summary>
	<brief_title>Blinded Study Topical Investigational Lotion Vs. Approved Cream Treatment Plaque Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Halobetasol</mesh_term>
	<mesh_term>Clobetasol</mesh_term>
	<criteria>Subjects male nonpregnant female ; 18 year age time screen . Subjects provide Institutional Review Board ( IRB ) approve write informed consent participate study . Subjects clinical diagnosis stable plaque psoriasis involve minimum 20 % body surface area Overall Disease Severity ( ODS ) score designate treatment area least 3 determined evaluate investigator . Subjects willing able apply study medication direct , comply study instruction commit followup visit duration study . Women childbearing potential ( WOCBP ) must negative urine pregnancy test Screening ( Part B ) Baseline Visits agree use effective form birth control duration study ( abstinence , stabilize oral contraceptive contraceptive patch least three month , implant , injection , IUD , NuvaRing® , condom spermicidal diaphragm spermicidal ) . Abstinence acceptable form birth control subject sexually active . Subjects become sexually active trial must agree use effective , nonprohibited form birth control duration study . Subjects spontaneously improve rapidly deteriorate plaque psoriasis , guttate , pustular , erythrodermic nonplaque form psoriasis . Subjects physical condition , Investigator 's opinion , might impair evaluation plaque psoriasis , adrenal axis function ( e.g. , Addison 's Disease , Cushing 's Syndrome ) expose subject unacceptable risk study participation . Subjects use phototherapy ( include laser ) , photochemotherapy systemic psoriasis therapy include methotrexate , retinoids , cyclosporine biologics within 30 day prior initiation study medication treatment . Subjects use systemic corticosteroid ( include oral intramuscular ) topical , inhale intranasal corticosteroid within 30 14 day , respectively , prior Part B Screening Visit and/or subject use systemic topical corticosteroid Screening Visit initiation treatment . Subjects prolong exposure natural artificial source ultraviolet radiation within 30 day prior initiation treatment intend exposure study think Investigator likely modify subject 's disease . Subjects use topical psoriatic therapy include tar , anthralin , retinoids , vitamin D analog ( e.g. , Dovonex® ) within 14 day prior initiation study medication treatment . Subjects use emollients/moisturizers area treat within one day prior initiation study medication treatment . Subjects currently use lithium plaquenil . Subjects currently use betablocking medication ( e.g. , propanolol ) angiotensin convert enzyme ( ACE ) inhibitor dose stabilize , opinion Investigator . Subjects history sensitivity ingredient study medication . Subjects pregnant , nurse plan pregnancy study period . Subjects currently enrol investigational drug device study . Subjects receive investigational drug investigational device within 30 day prior screen . Subjects previously enrol study treat study medication . Subjects irregular sleep schedule work night shift ( cortisol level exhibit physiological diurnal variation ) . Subjects screen CST post 30minute stimulation cortisol level ≤ 18 µg/dL .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>